Putnam’s Post

Merck Reports Data from the P-III (KEYLYNK-006) Study of Keytruda for Treatment of Metastatic Non-squamous NSCLC #merck #keytruda #nonsmallcelllungcancer #clinicaltrial #phase3 #metastatic #lynparza #chemotherapy #treatment #nsclc

Budget 2024: Relief for Cancer Patients and Increased PLI Allocation for Pharma The Union Budget 2024 brings some positive changes for the pharma and healthcare sectors: 🎗️ Cancer Patient Relief: Custom duties fully exempted on three AstraZeneca drugs - Trastuzumab Deruxtecan, Osimertinib, and Durvalumab. Medical Devices: Reduced basic custom duty on x-ray tubes and flat panel detectors, aiding domestic capacity addition. 📈 PLI Scheme: Increased allocation from ₹1,200 crore to ₹2,143 crore, boosting the pharma industry.

The landscape of NSCLC treatment is evolving rapidly, and personalized medicine is at the forefront. Our latest blog post dives into a massive dataset of 80,000+ ALK, 35,000+ ROS1, 11,000+ EGFR, and more FISH results, shedding light on the prevalence of key mutations and the potential for more precise treatment plans. For pharmaceutical companies seeking to target clinicians and patients effectively, this data is a game-changer. Learn how these insights can revolutionize NSCLC care: https://bit.ly/3SkGEGT #NSCLC #PersonalizedMedicine #RealWorldData #PrognosHealth

Making Sense of Radiopharmaceutical Ligands! Small Molecule vs Peptide vs Antibody. https://lnkd.in/gC5cmqP3 #Invenra #XCancer #Theranostics #Radiopharmaceuticals #Ligands

As early investors in Dyne Therapeutics, we are pleased to share they reported positive updates in their next-generation exon skipping program for Duchenne amenable to skipping exon 51. In their phase 1/2 Trial, Dyne-251 at dose of 10 mg/kg given once a month showed an average 3.2% normal dystrophin expression (7.6% normal dystrophin when adjusted for muscle content) at 6 months. Trends in functional improvements like the NSAA and other tests were observed, but non reached statistical significance at this time. Dyne-251 has fully enrolled cohorts for 20 and 40 mg/kg dosing and is reporting favorable safety profiles, while dystrophin and functional read outs for these higher doses will be coming in the future.    Dyne also reported positive safety, biomarker, functional, and patient reported outcome data in Type 1 Myotonic Dystrophy program (DM1), and anticipates providing updates by the end of the year on their plans for pursuing expedited FDA approvals in both DM1 and Duchenne. #FDA #DMD #DUCHENNE #CUREDUCHENNE #CLINICALTRIALS

#Radiopharmaceutical clinical trials face a host of logistical challenges, often leading to delays. Learn how we leveraged proven #RLT expertise to help our sponsor meet or beat all critical milestones, securing #FDA approval in under four years. https://bit.ly/3Z4vydo #clinicaltrials #Radioligand #isotopes #clinicalresearch #psicro #radiopharmaceuticals #theranostic #diagnostic #imagingagents #oncology

DelveInsight's comment: Fulzerasib emerges as a game-changer for KRAS G12C-mutated NSCLC with promising preliminary efficacy and an excellent safety profile in Phase II KROCUS Study!

Exploring the Impact of Radiopharmaceutical Manufacturing At AtomVie Global Radiopharma (AtomVie), we are at the forefront of producing high-quality radiopharmaceuticals that are transforming patient lives. Our services include cutting-edge processes such as analytical method development, tech transfer, qualification, and validation, leading to the clinical and commercial supply of radiopharmaceuticals and their global distribution. These services enable us to manufacture innovative agents for our clients under GMP standards, which can be applied across various fields, such as oncology, neurology, cardiology, and inflammation. Take a look at the transformative applications of radiopharmaceuticals in the slide below. Have you encountered any other new applications? We invite you to share your insights in the comments below and check out our website https://lnkd.in/eRfgP6FK to learn more about our services. Together, let's continue our mission of revolutionizing patient care with high-quality radiopharmaceuticals, one dose at a time. #AtomVieGlobalRadiopharma #radiopharmaceuticals #nuclearmedicine #manufacturingexcellence #patientoutcomes

I am delighted to share that review paper titled "Diagnosing Early Hepatocellular Carcinoma: A Review" accepted and published in the reputable journal Current Pharmaceutical Design, published by Bentham Science Publishers. An impact factor of 3.1 Early detection of hepatocellular carcinoma (HCC) is crucial for curative treatment. However, initial HCC is frequently asymptomatic, necessitating screening in high-risk patients with ultrasound and alpha-fetoprotein levels. Imaging with triphasic CT or MRI aids definitive diagnosis of small lesions, though biopsy may be required when findings are indeterminate. Timely diagnosis at an early stage significantly improves prognosis and treatment options for HCC patients.

Mission Therapeutics raises £25.2 million to accelerate its #mitophagy targeting lead drug candidates, #MTX325 and #MTX652, through clinical trials. The financing was jointly led by existing investors Pfizer, Sofinnova Partners, Roche, SR One Capital Management, IP Group plc, and Rosetta Capital Both MTX325 and MTX652 inhibit #USP30, a deubiquitylating enzyme (DUB) that constantly removes ubiquitin from mitochondria, limiting the removal of dysfunctional mitochondria. MTX325, a CNS penetrant which is a potential disease-modifying treatment for #Parkinson’s Disease, is about to enter Phase I trials; while peripherally-restricted MTX652 is currently in Phase II investigating cardiac surgery-associated kidney injury. Learn more about MTX325 and MTX652 using the link in the comments below. #DUBinhibitors #parkinsonsdisease #acutekidneyinjury #AKI